LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Sonida Senior Living Announces First Quarter 2025 Earnings Release Date and Conference Call

May 02, 2025 | Last Trade: US$24.51 0.12 -0.49

DALLAS / May 02, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its first quarter 2025 earnings results before the market opens for trading on Monday, May 12, 2025. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time.

The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes prior to the start of the call/webcast to ensure connectivity.

A webcast replay will be available on the Sonida IR website and accessible for replay for 12 months. A telephonic replay will be available for 7 days at (800) 770-2030, passcode 4619110.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including four owned through joint venture investments in consolidated entities, four owned through a joint venture investment in an unconsolidated entity, and one unoccupied), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page